Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-568.e14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22.

Article  CAS  PubMed  Google Scholar 

Camus V, Belot A, Oberic L, Sibon D, Ghesquières H, Thieblemont C, et al. Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022;6:6169–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kobayashi T, Kuroda J, Yokota I, Tanba K, Fujino T, Kuwahara S, et al. The Kyoto prognostic index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J. 2016;6:e383.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351–63.

Article  CAS  PubMed  Google Scholar 

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.

Article  CAS  PubMed  Google Scholar 

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403–15.

Article  CAS  PubMed  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20:31–42.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.

Article  PubMed  Google Scholar 

Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4:3268–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prince HM, Imrie K, Michael C, Stkwart AK, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: Identification of major prognostic groups. Br J Haematol. 1996;92:880–9.

Article  CAS  PubMed  Google Scholar 

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, et al. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2023;7:744–55.

Article  CAS  PubMed  Google Scholar 

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

Article  ADS  CAS  PubMed  Google Scholar 

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

Article  PubMed  Google Scholar 

Kobayashi T, Yamamoto K, Kagami Y, Machida R, Miyazaki K, Nakamura S, et al. Prognostic value of the Kyoto prognostic index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial. Jpn J Clin Oncol. 2022;52:583–8.

Article  PubMed  PubMed Central  Google Scholar 

Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–73.

Article  PubMed  PubMed Central  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  CAS  PubMed  Google Scholar 

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales M-A, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389:148–57.

Article  CAS  PubMed  Google Scholar 

Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399:2294–308.

Article  CAS  PubMed  Google Scholar 

Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer. 2014;135:362–70.

Article  CAS  PubMed  Google Scholar 

Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014;110:435–40.

Article  CAS  PubMed  Google Scholar 

Wang J, Gao K, Lei W, Dong L, Xuan Q, Feng M, et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget. 2017;8:5414–25.

Article  PubMed  Google Scholar 

Li YL, Gu KS, Pan YY, Jiao Y, Zhai ZM. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. BMC Cancer. 2014;14:341.

Katoh D, Ochi Y, Yabushita T, Ono Y, Hiramoto N, Yoshioka S, et al. Peripheral blood lymphocyte-to-monocyte ratio at relapse predicts outcome for patients with relapsed or refractory diffuse large B-cell lymphoma in the rituximab era. Clin Lymphoma Myeloma Leuk. 2017;17:e91–7.

Article  PubMed  Google Scholar 

Lee SF, Luque-Fernandez MA. Prognostic value of lymphocyte-To-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. BMJ Open. 2017;7:e017904.

Belotti A, Doni E, Bolis S, Rossini F, Casaroli I, Pezzatti S, et al. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large b-cell lymphoma patients in the rituximab era. Clin Lymphoma Myeloma Leuk. 2015;15:208–13.

Article  PubMed  Google Scholar 

Kumagai S, Tashima M, Fujikawa J, Iwasaki M, Iwamoto Y, Sueki Y, et al. Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. Int J Hematol. 2014;99:737–42.

Article  PubMed  Google Scholar 

Goy A, Feldman T, Leslie LA, Skarbnik AP, Wu T, Hansen E, et al. Prognostic value of the absolute lymphocyte to monocyte (ALC/AMC) ratio on overall survival among patients with mantle cell lymphoma. J Clin Oncol. 2017;35:e19030.

Article  Google Scholar 

Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, et al. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol. 2018;97:1009–18.

Article  PubMed  Google Scholar 

Lee SF, Ng TY, Spika D. Prognostic value of lymphocyte-monocyte ratio at diagnosis in Hodgkin lymphoma: a meta-analysis. BMC Cancer. 2019;19:338.

Romano A, Parrinello NL, Cerchione C, Consoli ML, Parisi M, Calafiore V, et al. The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer J. 2017;7:649.

Binder M, O’Byrne MM, Maurer MJ, Ansell S, Feldman A